$Galera Therapeutics(GRTX.US)$Galera reported a net loss of $(4.4) million, or $(0.08) per share, for the first quarter of 2024, compared to a net loss of $(17.7) million, or $(0.50) per share, for the same period in 2023.
$Galera Therapeutics(GRTX.US)$10% Shareholder Schneid Yair purchased 2.78 million shares of common stock on Apr 17, 2014 and Apr 17, 18, 19, 2024 at an average price of $0.2124 for a total value of $590.42K.
$Galera Therapeutics(GRTX.US)$Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.35) by 71.43 percent. This is a 82.76 percent increase over losses of $(0.58) per share from the same period last year.
Galera Therapeutics Insider Purchase: A Strategic Move or a Signal of Confidence? Galera Therapeutics Inc. (NASDAQ: GRTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for transformational improvements in cancer treatment, has recently seen a significant insider purchase. Yair Schneid, 10% owner of Galera, bought 932.4k shares at $0.18 each. This move is intriguing and deserves...
Jaguar8 : 盈利收益大幅提升
Trytosaveabit樓主 Jaguar8: 我知道對!在去年底獲得 CRL 之前,他們的交易價格在 2.00 以上!他們應該回答這件事嗎?格拉爾哈哈
Jaguar8 Trytosaveabit樓主: 希望
买跌不追涨 : 股價無反應
Trytosaveabit樓主 买跌不追涨: 而且我不期待會看到很多?也許在 RMH 期間一點?但是我也在尋找它來最終開始整體上升趨勢?我們就是如此!GL
查看更多評論...